Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 5 (UBA52P5) is a processed pseudogene derived from the parental gene UBA52 and located on human chromosome 7. It is annotated as a non-coding pseudogene and is considered a retrocopy—meaning it originated from reverse transcription and integration of UBA52 mRNA into the genome[6]. UBA52P5 does not encode a known functional protein and is not considered a drug target, receptor, enzyme, or transporter. Conservation of some pseudogenes has been noted, prompting research into whether some may have unrecognized roles[7][8]; however, there is no direct evidence supporting a role for UBA52P5 in biological processes, disease mechanisms, or drug interactions. It is primarily catalogued as a non-functional genetic element and should not be considered a true therapeutic or biological target[2][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 5 (UBA52P5).